

In the Claims

Please amend the claims by replacing all prior versions, and listings, of claims as follows:

Claims 1-27. (Canceled)

28. (Currently Amended) A method of treating a subject suffering from ~~a disease associated with demyelination of central nervous system axons~~multiple sclerosis comprising administering to the subject an effective amount of ~~an a~~humanized antibody directed against an epitope on glatiramer acetate or a F_{ab} fragment of the antibody in an amount effective to treat the ~~disease associated with demyelination of central nervous system axons~~subject.

29. (Canceled)

30. (Original) The method of claim 28, wherein the antibody is not cross-reactive with myelin basic protein (MBP).

31. (Currently Amended) The method of claim 28, wherein the antibody consists ~~essentially of~~ IgG1.

32. (Original) The method of claim 28, wherein the antibody does not react with mature oligodendrocytes.

33. (Original) The method of claim 28, wherein the antibody cross-reacts with spinal cord homogenate (SCH).

34. (Currently Amended) The method of claim 28, wherein the antibody ~~primarily~~ reacts with cells exhibiting a macrophage or microglial phenotype.
35. (Canceled)
36. (Original) The method of claim 28, wherein the antibody is a monoclonal antibody.
37. (Original) The method of claim 28, wherein the antibody is a polyclonal antibody.
- 38-40. (Canceled)
41. (Original) The method of claim 28, wherein the effective amount is an amount from 0.5 mg to 400 mg.
42. (Original) The method of claim 41, wherein the effective amount is an amount from 0.5 mg to 250 mg.
- 43-53. (Canceled)
54. (New) The method of claim 36, wherein the antibody is not cross-reactive with myelin basic protein (MBP).
55. (New) The method of claim 36, wherein the antibody consists of IgG1.
56. (New) The method of claim 36, wherein the antibody does not react with mature oligodendrocytes.

57. (New) The method of claim 36, wherein the antibody cross-reacts with spinal cord homogenate (SCH).
58. (New) The method of claim 36, wherein the antibody reacts with cells exhibiting a macrophage or microglial phenotype.
59. (New) The method of claim 36, wherein the effective amount is an amount from 0.5 mg to 400 mg.
60. (New) The method of claim 59, wherein the effective amount is an amount from 0.5 mg to 250 mg.